Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy.
Fiche du document
2008
- doi: 10.1038/sj.bjc.6604520
- issn: 0007-0920
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1038/sj.bjc.6604520
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/18665172
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1532-1827
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_3F481AA1AE025
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Multiple hemorrhagic sarcoma Idiopathic hemorrhagic sarcoma Kaposi sarcoma KS (Kaposi's sarcoma) Antiretroviral therapy, Highly active HAART (Chemotherapy)Citer ce document
S. Franceschi et al., « Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. », Serveur académique Lausannois, ID : 10.1038/sj.bjc.6604520
Métriques
Partage / Export
Résumé
Between 1984 and 2006, 12 959 people with HIV/AIDS (PWHA) in the Swiss HIV Cohort Study contributed a total of 73 412 person-years (py) of follow-up, 35 551 of which derived from PWHA treated with highly active antiretroviral therapy (HAART). Five hundred and ninety-seven incident Kaposi sarcoma (KS) cases were identified of whom 52 were among HAART users. Cox regression was used to estimate hazard ratios (HR) and corresponding 95% confidence intervals (CI). Kaposi sarcoma incidence fell abruptly in 1996-1998 to reach a plateau at 1.4 per 1000 py afterwards. Men having sex with men and birth in Africa or the Middle East were associated with KS in both non-users and users of HAART but the risk pattern by CD4 cell count differed. Only very low CD4 cell count (